Summary report OECD/EUPHA - Long COVID Policy Dialogue
This publication is part of the “Supporting long COVID patients: insights and action initiative (2024-2026)” of the European Commission.
Beyond childhood: why lifelong vaccination is a frontline defence against chronic disease
Guest article by the World Federation of Public Health Associations (WFPHA)
Effectiveness of nirsevimab immunisation on invasive pneumococcal disease in children nationwide in France: an observational cohort study
These findings suggest an additional benefit of nirsevimab implementation beyond RSV disease prevention, but further studies are needed.
Recombinant Influenza Vaccine and Influenza Outbreaks in US Nursing Homes: Results From a Pragmatic Cluster-Randomized Clinical Trial
These findings suggest that recombinant influenza vaccines may provide clinically meaningful facility-level benefits in long-term care settings during seasons with substantial influenza circulation.
High-dose vs standard-dose influenza vaccine in heart failure: the FLUNITY-HD pooled analysis
The results of prior randomized trials investigating the potential role of influenza vaccination in preventing severe clinical events in various HF populations have been mixed.
Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial
In adults aged 50 years or older, aQIVc was non-inferior and superior to aQIV for all four influenza strains and non-inferiority criteria for aQIVc versus QIVr were met for A/H1N1 and both B strains, but not A/H3N2.
Emergence and spread of NA-I223V and NA-S247N double-mutant A(H1N1)pdm09 influenza viruses with reduced oseltamivir susceptibility in the Netherlands and beyond, 2023 to 2026
These findings underscore the need for ongoing genomic and phenotypic monitoring of antiviral susceptibility.
Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2
Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk.